Coronavirus company news summary – JOYSBIO’s Covid-19 antigen test kit detects new strain – Europe approves Seegene’s saliva-based Covid-19 test kit

7 January 2021 (Last Updated January 7th, 2021 09:54)

JOYSBIO Biotechnology has developed the SARS-CoV-2 Antigen Rapid Test Kit, which is capable of detecting the new Covid-19 strain found in the UK and US. Referred to as SARS-CoV-2 VUI 202012/01, Variant of Concern 202012/01, VOC-202012/01, or lineage B.1.1.7, was identified first in England during the autumn of 2020, and later in France and the US as well.

A Prince of Songkhla University team in Thailand have developed a new Covid-19 test kit that shows 99% accuracy in detecting antibodies in the blood within 15 minutes. The kit has been approved by Thailand’s Food and Drug Administration (FDA) and will be produced at a rapid pace of 100,000 kits per day.

Sensus Healthcare has announced that Holy Name Medical Centre in Teaneck, New Jersey has acquired a Sensus low-dose radiation therapy system for treating pneumonia in Covid-19 patients. The SRT-100+™ and SRT-100 Vision™ systems are portable and can allow immediate treatment in an intensive care unit rather than having to transport patients to cancer treatment centres that increase the chances of exposure to the SARS-CoV-2 virus.

Seegene has been granted CE-IVD permits in Europe for its two in-vitro diagnostic saliva-based test kits that help in detecting the Covid-19 disease. The two test kits, Allplex SARS-CoV-2 Assay and Allplex SARS-CoV-2/FluA/FluB/RSV Assay, can detect four target genes for Covid-19 and simultaneously identify the new coronavirus and flu respectively.